Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) EBIT Margin (2021 - 2025)

Janux Therapeutics (JANX) has disclosed EBIT Margin for 5 consecutive years, with 352.51% as the latest value for Q3 2025.

  • On a quarterly basis, EBIT Margin rose 781195.0% to 352.51% in Q3 2025 year-over-year; TTM through Dec 2025 was 1576.67%, a 64309.0% decrease, with the full-year FY2025 number at 1576.67%, down 64309.0% from a year prior.
  • EBIT Margin was 352.51% for Q3 2025 at Janux Therapeutics, up from 8164.46% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 155.36% in Q2 2024 to a low of 8164.46% in Q3 2024.
  • A 5-year average of 1338.23% and a median of 843.51% in 2021 define the central range for EBIT Margin.
  • Peak YoY movement for EBIT Margin: tumbled -753622bps in 2024, then soared 781195bps in 2025.
  • Janux Therapeutics' EBIT Margin stood at 834.78% in 2021, then increased by 23bps to 642.04% in 2022, then fell by -2bps to 655.71% in 2023, then plummeted by -1145bps to 8164.46% in 2024, then soared by 96bps to 352.51% in 2025.
  • Per Business Quant, the three most recent readings for JANX's EBIT Margin are 352.51% (Q3 2025), 8164.46% (Q3 2024), and 155.36% (Q2 2024).